IPO Guru
Listed Mainboard

Rubicon Research IPO Review

Rubicon Research IPO has been reviewed by 7 analysts, and the overall consensus is Strong Apply — carrying a score of 97. Out of the 7 analysts who have covered this IPO, 6 recommend subscribing while 1 advises caution or avoidance — reflecting a broadly positive view from the analyst community.

The issue is priced in the band of ₹461-485 per share, with a minimum application size of 30 shares (minimum investment of approximately ₹14,550 at the upper band). Subscription ran from 09 Oct 2025 to 13 Oct 2025. The issue size is ₹1 crore, a mix of fresh issue and offer for sale. Scroll down for the full analyst breakdown and analyst-wise verdicts.

Abhishek Vohera, Founder of IPO Guru Researched & reviewed by Abhishek Vohera, Founder, IPO Guru Last updated Figures sourced from the RHP, BSE & NSE

Analyst verdict & score

One score out of 100, aggregated from every analyst verdict tracked for this issue. How it's calculated

Sentiment score
97/ 100
Strong Apply 6 of 7 recommend subscribing
How analysts voted
Apply 6
May apply 1
Not rated 2

Higher consensus indicates broader analyst agreement.

Detailed review

What the analyst reports say, grouped by the question you're likely asking.

General review

Rubicon Research is a pharmaceutical company whose revenue grew from ₹872.39 crore in FY24 to ₹1,296.22 crore in FY25, with operating margin near 20 percent and EBITDA of ₹267 crore. Five of the seven analysts covering it said subscribe, one advised caution and one gave no rating.

Listing gains

At the ₹485 upper band the notes value the issue at about 59.5 to 60 times FY25 earnings, which is a demanding multiple. Analysts justify it on scalability and growth rather than peer comparison, and one flags it as suited to high risk appetite. That pointed to a moderate listing.

Short-term strategy

The June 2025 quarter produced ₹356.95 crore of revenue and ₹79.74 crore of EBITDA at a 19.9 percent margin, tracking ahead of the FY25 run rate. Revenue grew about 49 percent in FY25. Sustaining that pace is what the high multiple requires in the near term.

Long-term strategy

The subscribe ratings rest on scalability in the pharmaceutical formulations business and continued strong revenue growth. Because the price already embeds roughly 60 times earnings, the long-term case depends entirely on growth persisting for several years rather than on any re-rating of the multiple.

How this is written: an AI-assisted summary of the 9 analyst reports listed below. It reports their views; IPO Guru does not make buy or sell recommendations.

Analyst reviews

Ordered by each analyst's track record over the past year; analysts still building one are listed last.

Latest IPO reviews

How analysts rated the most recent mainboard issues — and, where they have listed, how the call played out.

Frequently asked

Should I apply for Rubicon Research IPO?

The analyst consensus for Rubicon Research IPO tracked on this page is Strong Apply, with a score of 97/100. Out of 7 analysts who have reviewed this IPO, 6 recommend subscribing. IPO Guru does not make buy or sell recommendations. Read the individual analyst reports and consult a SEBI-registered advisor before investing.

What does the score of 97 mean for Rubicon Research IPO?

The score of 97 is an aggregate of all analyst ratings tracked for Rubicon Research IPO. A score in this range indicates strong analyst confidence — most analysts are recommending a subscribe. Read the individual analyst verdicts above for more context.

What was the actual listing price of Rubicon Research IPO?

Rubicon Research IPO listed on October 16, 2025 at ₹620, against the issue price of ₹485 — a gain of +27.84% (₹135 per share). View the full GMP history page for day-wise pre-listing trends.

What is the price band and lot size of Rubicon Research IPO?

Rubicon Research IPO was priced at ₹461-485 per share. The minimum lot size is 30 shares, making the minimum investment approximately ₹14,550 at the upper end of the price band. Subscription ran from 09 Oct 2025 to 13 Oct 2025.

Explore Rubicon Research IPO further

Analyst views are one input. Read them alongside the demand, the grey market and the filings before you decide.

Rubicon Research IPO review

A verdict is an opinion, not a guarantee.

IPO Guru collects analyst views, GMP, subscription and allotment for every Mainboard and SME issue. Weigh them together — and against the offer document — before you apply.

Join the WhatsApp channel Full IPO details

Disclaimer: Grey Market Premium (GMP) is for information purposes and is not a guarantee of listing price. Always consult your financial advisor before investing.

Consensus
Strong Apply
Score
97 / 100
Listed at
₹620
Full IPO details